Pernix Therapeutics Holdings Inc

Pernix Therapeutics — FY2011 Earnings Presentation

31 slides from Pernix Therapeutics's earnings presentation, Mar 7, 2012

  1. Slide 1: Pernix Therapeutics

    PERNIX., THERAPEUTICS PTX NYSE AMEX.

  2. Slide 2: Safe Harbor Statement

    The following presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward looking statements, whi

  3. Slide 3: Corporate Headquarters: The Woodlands, TX

    Corporate Headquarters: The Woodlands, TX Distribution Centers in Magnolia TX & Gonzales LA

  4. Slide 4: Pernix Overview

    Generic Business Platform Focused on Niche Markets Acquired Macoven Pharmaceuticals in September 2010; Launched 11 generic products in 2010 Pernix Overview Branded Prescription Pediatric Products Branded Prescription Gastroenterology Products Establish new specialty sales force of 30 representatives

  5. Slide 5: Investment Highlights

    § Swift, nimble and agile company with the ability to capitalize on new opportunities quickly § Demonstrated success with consistent revenue growth (41.9% 4-year CAGR) § Highly effective 55 person sales force able to adapt quickly to launch and promote existing and new products § Current Growth Driv

  6. Slide 6: Significant Net Revenue Growth in 2011

    § Net revenues expected to increase more than 64% between $20 and $22 million in Q4 2011, compared to $12.2 million for Q4 2010 § Net revenues expected to increase more than 78% between $59 and $61 million for the full year of 2011, compared to $33.2 million in 2010 § Earnings per share (EPS) expect

  7. Slide 7: Growth Opportunities Within Pediatrics

    Growth Opportunities Within Pediatrics Based on Total Number of Pediatric Prescriptions in 2010 (1) Current Markets Potential Markets The current Pernix markets have a $3.0 billion in brand sales potential Source: 1 - IMS Data Allergies & Asthma ADHD Pharyngitis & Strep Sinusitus & Bronchitis Acne &

  8. Slide 8: Successful Track Record of Acquisitions

    § Pernix has an active business development effort focused on acquiring complementary low-risk / under-marketed commercial products § Acquired Brovex for $450,000 and leveraged the Pernix sales force to grow the product to approximately $5.8m in sales within 6 months § Acquisitions of Cedax, Macoven

  9. Slide 9: Performance-Driven Sales Force

    § Significantly increased sales force to approximately 55 representatives from 30 in 2010 § Unique hiring process § Unlimited commission payout with modest base pay § Approximately 13 calls per day per sales rep § Focus on highly populated states and high-prescribing physicians § Demonstrated abilit

  10. Slide 10: Continued Strong Revenue Growth

    Continued Strong Revenue Growth ($ in millions) Net Sales Growth Revenue CAGR 2007-2011 * Based on preliminary unaudited results

  11. Slide 11: Strategic Plan for Future Growth

    Strategic Plan for Future Growth Grow sales of Cedax, Natroba and Macoven products; Expansion into Gastroenterology; Develop New Products Maximize value of Theobromine; Accretive acquisitions within pediatrics and other therapeutic areas Launch new products; Continue to expand into new markets and l

  12. Slide 12: Expansion into Gastroenterology

    Expansion into Gastroenterology § Broadens product portfolio § FDA-approved prescription product to treat GI disease § Licensed exclusive marketing rights in the U.S § Establish sales force in the first-half of 2012 • Approximately 30 sales reps § Launch expected in mid-year of 2012

  13. Slide 13: Product Portfolio

    Product Portfolio

  14. Slide 14: Product Portfolio

    Product Portfolio Allergies, congestion and cough Q3:2006 Allergies, congestion and cough Q2:2009 Allergies and congestion Q3:2008 Bronchitis, ear and throat infections Q2:2010 Topical treatment of head lice August:2011 Gastroenterology Mid-Year 2012 (Expected) Various generics GI Product 11 in 2010

  15. Slide 15: New Growth Driver - Cedax

    New Growth Driver - Cedax § CEDAX is a third generation oral cephalosporin indicated for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza or streptococcus pyogenes § Acquired the CEDAX product line from Shionogi

  16. Slide 16: Pediatrics - Middle Ear Infections

    § Over 5 Million cases of middle ear infections occur annually in children, which resulted in 10 million antibiotic prescriptions per year 1 § Middle ear infections are the most common illnesses experienced by babies and young children o Number one cause of consultations with physicians § Cedax (cef

  17. Slide 17: Effectiveness of CEDAX

    Effectiveness of CEDAX Source : 1) Craig, WA, Andes D. Pharmokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J. 1996; 15(3): 255-259. 2) Physicians’ Desk Reference. Montvale, NJ: Thomson Medical Economics Company, Inc. 2003. Available at http://www.pdr.net 3) Scaglio

  18. Slide 18: Strong Launch for New 180mg Cedax

    Strong Launch for New 180mg Cedax Strong growth in Cedax oral suspension total weekly prescriptions since launch of 180mg formulation in January 2011 (IMS)

  19. Slide 19: New Growth Driver - Natroba

    ■ Natroba (spinosad), branded prescription treatment for head lice o Received FDA approval in January 2011 ■ Exclusive co-promotion agreement with ParaPro ■ Launched in August 2011 for the lice season with adequate product supply by ParaPro ■ IP protection through 2021 ■ Natural non-neurotoxic pedic

  20. Slide 20: Strong Clinical Support - Natroba

    ■ Patients were 1,038 boys and girls age six months and older with active head lice infestations (pediculosis capitis) Strong Clinical Support - Natroba ■ Most participants in the Natroba groups (63.8% and 86.2%) needed only one application, whereas most participants in the permethrin groups (60.3%

  21. Slide 21: Lice Market & Sales Strategy

    § The U.S. Centers for Disease Control and prevention estimates between 6 to 12 million cases of head lice infestations each year § Direct and indirect costs of head lice infestations in U.S. estimated at over $1 billion 1 § Key issues with current therapies include growing resistance, toxicity, bla

  22. Slide 22: Macoven Pharmaceuticals

    § Q4 2010 - Completed acquisition of Macoven Pharmaceuticals, a generic business platform for Pernix o Provides the opportunity to diversify and grow revenues with generics and authorized generics o Management team started and successfully grew generic businesses o Strategy to launch pediatric and o

  23. Slide 23: Theobromine Update

    § Theobromine is a medical food candidate which is naturally present in all cocoa products and is an existing human metabolite of caffeine § Has been shown to suppress cough by acting on the vagus nerve § Proven efficacy and safety from a Phase III trial in South Korea; approved and marketed as a dr

  24. Slide 24: Summary

    Summary

  25. Slide 25: Key Milestones

    ü FDA approval of Natroba; Co-promotion with ParaPro January 2011 ü Launch of Cedax 180mg January 2011 ü Launch of Natroba August 2011 ü Generic Launches by Macoven H2:2011 ü Licensed Gastroenterology Product Q1:2012 ü Initiated ATM Offering Program Q1:2012 ü Licensed Pediatric Development Product Q

  26. Slide 26: Experienced Management Team

    Management Title Prior Company Experience Cooper Collins President and Chief Executive Officer Joined Pernix in 2003 David Becker Chief Financial Officer Adams Respiratory Therapeutics, Ernst & Young LLP Chuck Hrushka Vice President, Sales and Marketing Shionogi/Sciele Pharma, Sucampo Pharmaceutical

  27. Slide 27: Investment Highlights

    § Swift, nimble and agile company with the ability to capitalize on new opportunities quickly § Demonstrated success with consistent revenue growth (41.9% 4-year CAGR) § Highly effective 55 person sales force able to adapt quickly to launch and promote existing and new products § Current Growth Driv

  28. Slide 28: Financial Results

    Financial Results Through First Nine Months of 2011

  29. Slide 29: Continued Growth in 2011

    ($, in millions except per share data) Three Months Ended September 30 Nine Months Ended September 30 2011 2010 2011 2010 Net Sales $17.1 $7.8 $39.2 $21.0 Gross Profit 9.3 (1) 6.4 25.5 (1) 17.7 SG&A Expense 5.4 (2) 3.5 14.9 9.4 Income from Operations 3.0 2.1 7.1 6.7 Adjusted EBITDA 3.6 2.7 8.8 (3) 7

  30. Slide 30: Solid Financial Position

    As of September 30, 2011 ($, in millions) Cash and Cash Equivalents $27.6 Accounts Receivable, net 23.7 Inventory, net 7.5 Working Capital 38.4 Total Assets 77.5 Total Debt 6.0 Solid Financial Position

  31. Slide 31: Pernix Therapeutics

    PERNIX., THERAPEUTICS PTX NYSE AMEX.

Pernix Therapeutics Holdings — FY2011 Earnings Presentation on 6ix